Lupin, Natco get FDA Eribulin approval
Analysis based on 8 articles · First reported Jun 03, 2026 · Last updated Jun 03, 2026
The approval of a generic Eribulin Mesylate Injection by the United States — Food and Drug Administration for Lupin (company) and Natco Pharma is expected to positively impact their stock prices due to increased market share in the oncology sector. Conversely, Eisai, the original manufacturer of Eribulin, may experience a negative market sentiment as its product will face new generic competition, potentially affecting its sales and revenue.
Lupin (company) and its alliance partner Natco Pharma have received approval from the United States — Food and Drug Administration (U.S. FDA) for Natco Pharma's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials. This generic drug is bioequivalent to Eisai's reference listed drug, Eribulin Injection. Eribulin Mesylate Injection is indicated for the treatment of adults with metastatic breast cancer and unresectable or metastatic liposarcoma. The approval is a significant milestone for both Lupin (company) and Natco Pharma, expanding their portfolios in the United States market and offering a cost-effective alternative to existing treatments. Eribulin had estimated annual U.S. sales of $43.7 million, indicating a substantial market opportunity for the generic version.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard